

Inventor(s): BOUCHARD *et al.*
Application No.: 10/661,780
Attorney Docket No.: 098501-0305998

I. AMENDMENT TO THE SPECIFICATION

Please amend the paragraph beginning on page 1, line 5 as follows:

-- This is a continuation of U.S. Patent Appl. No. 09/053,152, filed April 1, 1998, now abandoned, which is a continuation-in-part of application serial no. U.S. Patent Appl. No. 08/786,937, filed January 22, 1997, which is based on provisional application serial no. claims priority to U.S. Provisional Patent Appl. No. 60/011,282, filed February 7, 1996, the contents of each of which are incorporated herein by reference.—

Please insert the following paragraph on page 10, line 1.

--Brief Description of the Drawing

Figure 1 shows monitoring of important reproductive hormones in a female patient (patient no. 2L/07) treated with subcutaneous injection of Cetrorelix Acetat-Lyophilisat. The hormone levels of luteinizing hormone (LH) ($\mu\text{g/l}$) (\circ), follicular stimulating hormone (FSH) ($\mu\text{g/l}$) (+), progesterone ($\mu\text{g/l}$) (\bullet), and oestradiol (E_2) (ng/l) (\blacktriangledown) were measured in female patient number 2L/07 at time intervals one month (11/10/1995) and four consecutive days before (12/05/1995-12/09/1995) a dual dose regimen of Cetrorelix (3mg) was administered subcutaneously on 12/10/1995 and 12/11/1995. The patient's LH, FSH, progesterone and oestradiol levels were measured afterward between 12/11/1995 and 12/14/1995 wherein ovulation in the patient was induced with human chorionic gonadotrophin (HCG) on 12/14/1995. The patients LH, FSH, progesterone, and oestradiol levels were also measured after HCG treatment through ovum pick up (OPU; 12/16/1995), and embryo transfer (ET) on 12/18/1995. Hormone levels were also measured on the 4th and (12/22/1995) and 16th day after ET(1/3/1996). —